New clinical data on AB-DENTALAC™ strains
AB-DENTALAC strains were selected from a long list of potential bacteria, and have been widely studied since, with its first publication in 2012. The probiotic blend has shown inhibitory activity against several oral pathogens and low acidogenic activity, properties key to support a healthy oral microbiota.
Following the 2012 publication, the strains were tested in a randomized trial in subjects with gingivitis, as well as in another randomized trial in subjects with oral pain after mandibular extraction. Results were positive in all trials, suggesting AB-DENTALAC supplementation as a valid, preventive or coadjutant treatment for oral pathologies, including gingivitis and periodontitis.
AB-DENTALAC is a probiotic solution that supports the diversity and functionality of the oral microbiota.
Recently, more clinical data of the product has been published in the Journal of Clinical and Experimental Dentistry. The study was a double-blind, placebo-controlled trial that tested the capacity of AB-DENTALAC strains to impact oral microbiota. Subjects with healthy gingiva or mild gingivitis received probiotic chewing gum or placebo for 6 weeks. Results showed a significant increase of L. brevis and L. plantarum bacteria populations in the oral cavity of the probiotic group compared to placebo, with correlated effects on oral health (reduction in dental plaque).
As growing evidence confirms the impact of oral microbiota dysbiosis in oral disease, AB-DENTALAC strains have been shown to favourably impact oral health, with clinically proven effects on the oral microbiome. This evidence supports a less known, but promising field in probiotics development.
AB-DENTALAC latest clinical trial is already available on the publisher’s website, still pending issue assignment
Authors: Claudia Prat (Human Biologist)
